Results 1 to 10 of about 405 (144)

Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review [PDF]

Pathogens
Cefepime-enmetazobactam is a novel β-lactam/β-lactamase inhibitor combination showing good activity against multidrug-resistant (MDR) Gram-negative bacteria producing a variety of β-lactamases.
Matthew E. Falagas, Laura T. Romanos, Dimitrios S. Kontogiannis, Katerina Tsiara, Stylianos A. Kakoullis   +4 more
doaj   +4 more sources

Diagnostic algorithm for the detection of carbapenemases and extended-spectrum β-lactamases in carbapenem-resistant Pseudomonas aeruginosa [PDF]

Microbiology Spectrum
Pseudomonas aeruginosa can acquire carbapenem resistance through various mechanisms, including genomic mutations leading to the overexpression of efflux pumps, intrinsic AmpC-β-lactamase, and/or reduced permeability, and/or through the acquisition of ...
Stefano Mancini, Laia Garcia-Verellen, Helena M. B. Seth-Smith, Peter M. Keller, Natalia Kolesnik-Goldmann, Muhammad Ali Syed, Irfan Ullah, Vladimira Hinic, Tim Roloff, Adrian Egli, Oliver Nolte   +10 more
doaj   +4 more sources

In vivo efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing Klebsiella pneumoniae [PDF]

Microbiology Spectrum
Cefepime/enmetazobactam is a new β-lactam/β-lactamase inhibitor combination with broad-spectrum activity against multidrug-resistant Enterobacterales, including OXA-48-producing isolates. Furthermore, cefepime and enmetazobactam have demonstrated similar
S. Albac, N. Anzala, P. Chavanet, N. Dunkel, J. Quevedo, A. Santerre Henriksen, D. Croisier   +6 more
doaj   +4 more sources

Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics [PDF]

Pharmaceuticals
The global spread of multidrug-resistant (MDR) Gram-negative bacteria, particularly extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, presents a significant public ...
Davide Carcione, Gioconda Brigante, Antonella Carducci, Jari Intra, Simone Ambretti, Floriana Campanile, Gabriele Arcari, Nicasio Mancini, Dario Cattaneo, Floriana Gona, Mariagrazia Perilli, Alessandra Piccirilli, Nicholas Geremia, Verena Zerbato, Stefano Di Bella, Giovanna Maria Nicolò, Luigi Principe   +16 more
doaj   +2 more sources

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics [PDF]

Pathogens
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou, Panagiotis Stathopoulos, Christos Vrysis, Iva D. Tzvetanova, Matthew E. Falagas   +4 more
doaj   +2 more sources

β-Lactam/β-Lactamase Inhibitor Combinations in Sepsis-Associated Acute Kidney Injury and Renal Replacement Therapy [PDF]

Antibiotics
Sepsis-associated acute kidney injury (SA-AKI) often requires renal replacement therapy (RRT), which markedly alters antimicrobial pharmacokinetics (PK) and pharmacodynamics (PD). Novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations broaden options
Antonio Lacquaniti, Valentina Pistolesi, Antonella Smeriglio, Domenico Santoro, Cristina Iannetti, Giuseppe Lentini, Roberto Chimenz, Valeria Chirico, Domenico Trombetta, Santo Morabito, Paolo Monardo   +10 more
doaj   +2 more sources

Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis [PDF]

Journal of Comparative Effectiveness Research
Aim: Compared with uncomplicated urinary tract infections (UTIs), complicated UTIs (cUTIs) including acute pyelonephritis (AP) presentwith significant morbidity, a higher risk of treatment failure and typically require longer courses of treatment, or ...
Florian Wagenlehner, Veronica Rico Caballero, Vikalp Maheshwari, Ayantika Biswas, Priyanka Saini, Juan Quevedo, Juergen Polifka, Leonardo Ruiz, Sandrine Cure   +8 more
doaj   +2 more sources

Antimicrobial activity of cephamycins and β-lactam/β-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula [PDF]

Scientific Reports
This study investigated the in vitro antimicrobial activity of cephamycins and novel β-lactam/β-lactamase inhibitor combinations, against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates.
Yu Mi Wi, Ji Young Choi, Da Eun Lee, So Hyun Jun, Ki Tae Kwon, Kwan Soo Ko   +5 more
doaj   +2 more sources

Nephrotoxicity of New Antibiotics: A Systematic Review [PDF]

Toxics
Drug-induced nephrotoxicity is a common and serious problem in clinical practice. We conducted a systematic review of studies reporting nephrotoxicity events associated with antibiotics approved since 2018.
Panagiotis Stathopoulos, Laura T. Romanos, Charalampos Loutradis, Matthew E. Falagas   +3 more
doaj   +2 more sources

Revitalizing cephalosporins: The promise of β-lactamase inhibitor combinations [PDF]

GMS Hygiene and Infection Control
This review explore the rise of multidrug-resistant (MDR) Gram-negative bacteria, highlighting β-lactamase inhibitor combinations as crucial therapeutic options.
Marzooka, Kazi-Chishti, Sajed, Shaikh, Dehghan, Mohamed Hassan, Bilal, Kazi, Imaan, Rumani   +4 more
doaj   +2 more sources